OUS_Viatris_Logo_Verti_RGB

This promotional webinar has been commissioned and funded by Viatris and developed in partnership with GuidelinesSee below for full disclaimer.

Products and brand names are mentioned.

Intended for UK healthcare professionals.

View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.

 

This 1-hour Guidelines   webinar:

  • discusses the oestrogen deficiency symptoms associated with the menopause
  • reviews the role of progestogen and why it is so important
  • looks at the risk profiles associated with the progestogen component of HRT and how they differ.

Read the prescribing HRT containing dydrogesterone algorithm here

Watch a short video on the role of progestogen here

This promotional webinar has been commissioned and funded by Viatris and developed in partnership with Guidelines. Viatris commissioned the speakers, and paid their honorarium. The views and opinions of the presenters are not necessarily those of Viatris, Guidelines, its publisher, advisers, or advertisers. No part of this webinar may be reproduced in any form without the permission of the publisher.

FEM-2021-0347

Date of preparation: March 2022